Quickstart Highlights

PNC-27 is a synthetic 32‑amino‑acid peptide containing an HDM‑2‑binding domain linked to a membrane‑penetrating sequence, studied preclinically for its selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 complexes^[1][2]. No human clinical trials exist, and the FDA explicitly warns that PNC-27 products are unapproved and lack established safety data^[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

• Reconstitute: Add 3.0 mL bacteriostatic water → 10 mg/mL concentration.
• Typical daily range: 100–500 mcg once daily (gradual titration).
• Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Protocol Overview

Concise summary of the once‑daily regimen.

• Goal: Educational exploration of a p53‑derived peptide studied preclinically for selective cancer‑cell membrane disruption^[1][2].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 100–500 mcg daily with gradual titration.
• Reconstitution: 3.0 mL per 30 mg vial (10 mg/mL) for simplified unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

• Start: 100 mcg daily for 1–2 weeks; increase by ~100 mcg every 2 weeks as tolerated.
• Target: 300–500 mcg daily by Weeks 5–16.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality^[5].

• Lyophilized: Store at −20 °C (−4 °F) or colder (−80 °C / −112 °F ideal) in dry, dark conditions; short‑term refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for days to weeks.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Regulatory Warning: PNC-27 has no FDA approval and no established human safety data^[3]. This information is strictly educational.

How This Works

PNC-27 is a chimeric peptide consisting of a segment derived from the p53 tumor suppressor protein (residues 12–26) fused to a membrane‑penetrating leader sequence^[1]. Preclinical studies indicate that PNC-27 selectively binds to HDM‑2 expressed on the surface of cancer cells, inducing membrane destabilization and necrotic cell death while sparing normal cells^[2][6]. Research in mouse tumor models has demonstrated inhibition of cancer cell growth via intraperitoneal administration^[4]. No human clinical studies have been conducted, and all dosing protocols remain theoretical extrapolations from preclinical work.

Potential Benefits & Side Effects

Observations from preclinical literature only—no human data available.

• Preclinical studies suggest selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 while sparing normal cells^[2][6].
• Mechanism involves direct membrane lysis rather than apoptosis in affected cells^[7].
• No human safety data: The FDA explicitly warns that PNC-27 safety and efficacy have not been established^[3].
• Possible injection‑site reactions (redness, irritation) may occur with subcutaneous administration.

Lifestyle Factors

General supportive strategies (not specific to PNC-27).

• Maintain a balanced, nutrient‑dense diet to support overall metabolic function.
• Prioritize adequate sleep and stress management for immune and recovery support.
• Consult qualified healthcare professionals before any experimental peptide use.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources^[8][9].

• Clean the vial stopper and skin with alcohol; allow to dry.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[8].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[9].
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[10].

Recommended Source

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Shop at Amino Labs

References